1-7 of 7
Shirish M. Gadgeel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Available to Purchase
Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace L. Akerley, III, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3641–3649.
https://doi.org/10.1158/1078-0432.CCR-22-3947
Published: 15 September 2023
View articletitled, Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Open the PDF for Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) in another window
Includes: Supplementary data
Journal Articles

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

Open Access
Rafal Dziadziuszko, Solange Peters, Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Krzysztof Konopa, Johannes Noé, Malgorzata Nowicka, Walter Bordogna, Peter N. Morcos, Vlatka Smoljanovic, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1800–1808.
https://doi.org/10.1158/1078-0432.CCR-21-2840
Published: 02 May 2022
View articletitled, Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Open the PDF for Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial in another window
Includes: Supplementary data
Journal Articles

Abstract S10-02: Using real-world data (RWD) from an integrated platform for rapid analysis of patients with cancer with and without COVID-19 across distinct health systems

Free
Shirish M. Gadgeel, Michael A. Thompson, Monika A. Izano, Clara Hwang, Tom Mikkelsen, James L. Weese, Frank M. Wolf, Andrew Schrag, Sheetal Walters, Harpreet Singh, Jonathan Hirsch, Thomas D. Brown, Paul G. Kluetz
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S10-02.
https://doi.org/10.1158/1557-3265.COVID-19-S10-02
Published: 15 September 2020
View articletitled, Abstract S10-02: Using real-world data (RWD) from an integrated platform for rapid analysis of patients with cancer with and without COVID-19 across distinct health systems
Journal Articles

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

Free
David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny M. Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2403–2413.
https://doi.org/10.1158/1078-0432.CCR-18-1341
Published: 15 April 2019
View articletitled, Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Free
Valentine M. Macaulay, Mark R. Middleton, S. Gail Eckhardt, Charles M. Rudin, Rosalyn A. Juergens, Richard Gedrich, Sven Gogov, Sean McCarthy, Srinivasu Poondru, Andrew W. Stephens, Shirish M. Gadgeel
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2897–2907.
https://doi.org/10.1158/1078-0432.CCR-15-2218
Published: 14 June 2016
View articletitled, Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Free
Eric B. Haura, Alejandro D. Ricart, Timothy G. Larson, Philip J. Stella, Lyudmila Bazhenova, Vincent A. Miller, Roger B. Cohen, Peter D. Eisenberg, Paulina Selaru, Keith D. Wilner, Shirish M. Gadgeel
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2450–2457.
https://doi.org/10.1158/1078-0432.CCR-09-1920
Published: 14 April 2010
View articletitled, A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design

Free
Shirish M. Gadgeel, Antoinette Wozniak, Ramesh R. Boinpally, Richard Wiegand, Lance K. Heilbrun, Vikas Jain, Ralph Parchment, Dimitrios Colevas, Marvin B. Cohen, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6233–6239.
https://doi.org/10.1158/1078-0432.CCR-05-0127
Published: 06 September 2005
View articletitled, Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design
Open the PDF for Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design in another window